More drug, fewer jabs: Novartis' Sandoz eyes EMA nod for high-concentration Humira copy

Novartis’ Sandoz is pushing to wipe out an advantage AbbVie’s Humira enjoys over its biosimilar rival in the EU, securing regulatory acceptance of a filing for a high-concentration formulation of the autoimmune treatment.